ARQL - ArQule, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
1.11
-0.02 (-1.77%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close1.13
Open1.13
Bid1.07 x 500
Ask1.28 x 1100
Day's Range1.09 - 1.15
52 Week Range0.92 - 1.68
Volume516,917
Avg. Volume149,232
Market Cap79M
Beta1.70
PE Ratio (TTM)-2.88
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Thomson Reuters StreetEvents2 months ago

    Edited Transcript of ARQL earnings conference call or presentation 4-Aug-17 1:00pm GMT

    Q2 2017 ArQule Inc Earnings Call

  • Associated Press3 months ago

    ArQule reports 2Q loss

    On a per-share basis, the Burlington, Massachusetts-based company said it had a loss of 10 cents. The company's shares closed at $1.10. A year ago, they were trading at $1.66. _____ This story was generated ...

  • Thomson Reuters StreetEvents6 months ago

    Edited Transcript of ARQL earnings conference call or presentation 3-May-17 1:00pm GMT

    Q1 2017 ArQule Inc Earnings Call

  • Associated Press6 months ago

    ArQule reports 1Q loss

    The Burlington, Massachusetts-based company said it had a loss of 11 cents per share. The company's shares closed at 98 cents. A year ago, they were trading at $1.63. _____ This story was generated by ...

  • Capital Cube7 months ago

    ETFs with exposure to ArQule, Inc. : April 5, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to ArQule, Inc. Here are 5 ETFs with the largest exposure to ARQL-US. Comparing the performance and risk of ArQule, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)

  • ArQule, Inc. :ARQL-US: Earnings Analysis: Q4, 2016 By the Numbers : March 21, 2017
    Capital Cube7 months ago

    ArQule, Inc. :ARQL-US: Earnings Analysis: Q4, 2016 By the Numbers : March 21, 2017

    Categories: Yahoo Finance Get free summary analysis ArQule, Inc. reports financial results for the quarter ended December 31, 2016. We analyze the earnings along side the following peers of ArQule, Inc. – Infinity Pharmaceuticals, Inc., Eli Lilly and Company, Curis, Inc., Amgen Inc., Cytokinetics, Incorporated, Exelixis, Inc. and Array BioPharma Inc. (INFI-US, LLY-US, CRIS-US, AMGN-US, CYTK-US, EXEL-US and ... Read more (Read more...)

  • ArQule, Inc. :ARQL-US: Earnings Analysis: 2016 By the Numbers : March 14, 2017
    Capital Cube7 months ago

    ArQule, Inc. :ARQL-US: Earnings Analysis: 2016 By the Numbers : March 14, 2017

    Categories: Yahoo Finance Get free summary analysis ArQule, Inc. reports financial results for the year ended December 31, 2016. We analyze the earnings along side the following peers of ArQule, Inc. – Eli Lilly and Company, Curis, Inc., Amgen Inc., Cytokinetics, Incorporated, Exelixis, Inc. and Array BioPharma Inc. (LLY-US, CRIS-US, AMGN-US, CYTK-US, EXEL-US and ARRY-US) that have also ... Read more (Read more...)

  • Thomson Reuters StreetEvents7 months ago

    Edited Transcript of ARQL earnings conference call or presentation 7-Mar-17 2:00pm GMT

    Q4 2016 ArQule Inc Earnings Call

  • Associated Press7 months ago

    ArQule reports 4Q loss

    On a per-share basis, the Burlington, Massachusetts-based company said it had a loss of 10 cents. The biotechnology company posted revenue of $1.2 million in the period. For the year, the company reported ...

  • Investopedia8 months ago

    ArQule Liver Cancer Drug Fails Phase 3 Trial

    ArQule’s liver cancer drug ARQ 197 failed a late-stage clinical trial.

  • ArQule, Inc. (ARQL)’s Liver Cancer Drug Fails: What’s Next?
    Insider Monkey8 months ago

    ArQule, Inc. (ARQL)’s Liver Cancer Drug Fails: What’s Next?

    ArQule, Inc. (NASDAQ:ARQL) took a real hit at the end of last week, as the company announced data from a late stage oncology trial. The data did not read out as hoped, and ArQule currently trades for a close to 20% discount to its Friday morning open price. The drug is the company’s lead asset, […]

  • 24/7 Wall St.8 months ago

    Sabre Corp., L Brands Dip into Friday’s 52-Week Low Club

    L Brands, DDR, Sabre Corp., and ArQule posted new 52-week lows on Friday.

  • ArQule (ARQL) Catches Eye: Stock Moves 7.2% Higher
    Zacks9 months ago

    ArQule (ARQL) Catches Eye: Stock Moves 7.2% Higher

    ArQule, Inc. (ARQL) was a big mover last session, as the company saw its shares rise over 7% on the day.

  • Capital Cube10 months ago

    ETFs with exposure to ArQule, Inc. : December 21, 2016

    Categories: ETFs Yahoo Finance Click here to see latest analysis ETFs with exposure to ArQule, Inc. Here are 5 ETFs with the largest exposure to ARQL-US. Comparing the performance and risk of ArQule, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)

  • How ArQule, Inc. (ARQL) Stacks Up Against Its Peers
    Insider Monkey10 months ago

    How ArQule, Inc. (ARQL) Stacks Up Against Its Peers

    The Insider Monkey team has completed processing the quarterly 13F filings for the September quarter submitted by the hedge funds and other money managers included in our extensive database. Most hedge funds have been producing disappointing net returns in recent years, however that was partly due to the poor performance of small-cap stocks in general. […]

  • Could Trump Tax Cut Plans, Republican Congress Spur Biotech M&A?
    Investor's Business Daily11 months ago

    Could Trump Tax Cut Plans, Republican Congress Spur Biotech M&A?

    Donald Trump could create an M&A-friendly tax scenario, prodding more acquisitions from the small- and mid-cap biotech pool.

  • ArQule, Inc. :ARQL-US: Earnings Analysis: Q3, 2016 By the Numbers : November 8, 2016
    Capital Cube11 months ago

    ArQule, Inc. :ARQL-US: Earnings Analysis: Q3, 2016 By the Numbers : November 8, 2016

    Categories: Yahoo Finance Get free summary analysis ArQule, Inc. reports financial results for the quarter ended September 30, 2016. We analyze the earnings along side the following peers of ArQule, Inc. – Eli Lilly and Company, Amgen Inc., AVEO Pharmaceuticals, Inc., Cytokinetics, Incorporated, Exelixis, Inc. and Array BioPharma Inc. (LLY-US, AMGN-US, AVEO-US, CYTK-US, EXEL-US and ARRY-US) that have ... Read more (Read more...)

  • Thomson Reuters StreetEvents11 months ago

    Edited Transcript of ARQL earnings conference call or presentation 7-Nov-16 2:00pm GMT

    Q3 2016 ArQule Inc Earnings Call